BRPI0416227B8 - micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit - Google Patents
micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kitInfo
- Publication number
- BRPI0416227B8 BRPI0416227B8 BRPI0416227A BRPI0416227A BRPI0416227B8 BR PI0416227 B8 BRPI0416227 B8 BR PI0416227B8 BR PI0416227 A BRPI0416227 A BR PI0416227A BR PI0416227 A BRPI0416227 A BR PI0416227A BR PI0416227 B8 BRPI0416227 B8 BR PI0416227B8
- Authority
- BR
- Brazil
- Prior art keywords
- microparticles
- kit
- pharmaceutical composition
- somatostatin analogues
- somatostatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
micropartículas compreendendo análogos de somatostatina. a presente invenção refere-se a micropartículas compreendendo um análogo de somatostatina incrustadas em uma matriz polimérica biocompatível e farmacologicamente aceitável para uma liberação de longa ação e composições farmacêuticas compreendendo essas micropartículas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0326602.0 | 2003-11-14 | ||
GB0326602A GB0326602D0 (en) | 2003-11-14 | 2003-11-14 | Organic compounds |
GB0406241.0 | 2004-03-19 | ||
GB0406241A GB0406241D0 (en) | 2004-03-19 | 2004-03-19 | Organic compounds |
PCT/EP2004/012870 WO2005046645A1 (en) | 2003-11-14 | 2004-11-12 | Microparticles comprising somatostatin analogues |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0416227A BRPI0416227A (pt) | 2007-01-02 |
BRPI0416227B1 BRPI0416227B1 (pt) | 2019-06-18 |
BRPI0416227B8 true BRPI0416227B8 (pt) | 2021-05-25 |
Family
ID=34593737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0416227A BRPI0416227B8 (pt) | 2003-11-14 | 2004-11-12 | micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit |
Country Status (31)
Country | Link |
---|---|
US (3) | US7759308B2 (pt) |
EP (1) | EP1686964B9 (pt) |
JP (1) | JP4682145B2 (pt) |
KR (1) | KR101233892B1 (pt) |
AR (1) | AR047310A1 (pt) |
AT (1) | ATE455537T1 (pt) |
AU (1) | AU2004289055C1 (pt) |
BR (1) | BRPI0416227B8 (pt) |
CA (1) | CA2541944C (pt) |
CY (2) | CY1110293T1 (pt) |
DE (1) | DE602004025271D1 (pt) |
DK (1) | DK1686964T3 (pt) |
EC (1) | ECSP066565A (pt) |
ES (1) | ES2339026T3 (pt) |
HK (1) | HK1093682A1 (pt) |
HR (1) | HRP20100190T1 (pt) |
IL (1) | IL175286A (pt) |
IS (1) | IS8480A (pt) |
LU (1) | LU92701I2 (pt) |
MA (1) | MA28155A1 (pt) |
MX (1) | MXPA06005357A (pt) |
MY (1) | MY158342A (pt) |
NO (2) | NO337172B1 (pt) |
NZ (1) | NZ546788A (pt) |
PE (1) | PE20050581A1 (pt) |
PL (1) | PL1686964T3 (pt) |
PT (1) | PT1686964E (pt) |
RU (1) | RU2404749C2 (pt) |
SI (1) | SI1686964T1 (pt) |
TW (1) | TWI295178B (pt) |
WO (1) | WO2005046645A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
ES2755032T3 (es) * | 2005-12-22 | 2020-04-21 | Novartis Ag | Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido |
KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
AR066677A1 (es) * | 2007-05-24 | 2009-09-02 | Novartis Ag | Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas. |
EP2247282B1 (en) * | 2008-01-30 | 2014-08-20 | Novartis AG | Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
WO2009123903A1 (en) * | 2008-04-03 | 2009-10-08 | Zymogenetics, Inc. | Hemostatic microspheres |
JP5721624B2 (ja) | 2008-07-08 | 2015-05-20 | ノバルティス アーゲー | 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用 |
AR074603A1 (es) * | 2008-12-15 | 2011-01-26 | Novartis Ag | Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit |
US8822610B2 (en) | 2008-12-22 | 2014-09-02 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US8815971B2 (en) | 2008-12-22 | 2014-08-26 | ATRP Solutions, Inc. | Control over controlled radical polymerization processes |
US9783628B2 (en) | 2009-04-23 | 2017-10-10 | ATRP Solutions, Inc. | Dual-mechanism thickening agents for hydraulic fracturing fluids |
US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
WO2010123574A1 (en) | 2009-04-23 | 2010-10-28 | Atrp Solutions Inc | Star macromolecules for personal and home care |
US9587064B2 (en) | 2010-12-08 | 2017-03-07 | ATRP Solutions, Inc. | Salt-tolerant star macromolecules |
WO2013131879A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | New application for pasireotide |
CN105189643B (zh) | 2012-08-30 | 2019-01-15 | 派诺聚合物技术公司 | 用于水力压裂液的双重机制增稠剂 |
MX2015009938A (es) | 2013-02-04 | 2015-10-05 | Atrp Solutions Inc | Macromoleculas en forma de estrella tolerantes a las sales. |
CA2903769A1 (en) | 2013-03-11 | 2014-10-09 | Durect Corporation | Injectable controlled release composition comprising high viscosity liquid carrier |
TW201605488A (zh) * | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及/或治療多囊腎病之藥物 |
CA2956431C (en) | 2014-07-03 | 2023-01-31 | ATRP Solutions, Inc. | Surfactant-compatible star macromolecules |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
WO1998032423A1 (en) * | 1997-01-29 | 1998-07-30 | Takeda Chemical Industries, Ltd. | Sustained-release microspheres, their production and use |
EP1240896A3 (en) * | 1998-07-23 | 2003-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Encapsulation of water soluble peptides |
ES2185373T3 (es) * | 1998-07-23 | 2003-04-16 | Sod Conseils Rech Applic | Encapsulacion de peptidos solubles en agua. |
WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
NZ526127A (en) | 1999-08-18 | 2005-02-25 | Sod Conseils Rech Applic | Use of a somatostatin analog in the manufacture of a medicament |
GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
JP4679822B2 (ja) * | 2002-03-13 | 2011-05-11 | ノバルティス アーゲー | 医薬微粒子 |
MY158342A (en) * | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
-
2004
- 2004-11-09 MY MYPI20044662A patent/MY158342A/en unknown
- 2004-11-11 AR ARP040104157A patent/AR047310A1/es not_active Application Discontinuation
- 2004-11-12 DE DE602004025271T patent/DE602004025271D1/de active Active
- 2004-11-12 ES ES04797866T patent/ES2339026T3/es active Active
- 2004-11-12 SI SI200431378T patent/SI1686964T1/sl unknown
- 2004-11-12 CA CA2541944A patent/CA2541944C/en active Active
- 2004-11-12 KR KR1020067009270A patent/KR101233892B1/ko active IP Right Grant
- 2004-11-12 US US10/579,186 patent/US7759308B2/en active Active
- 2004-11-12 DK DK04797866.3T patent/DK1686964T3/da active
- 2004-11-12 MX MXPA06005357A patent/MXPA06005357A/es active IP Right Grant
- 2004-11-12 TW TW093134728A patent/TWI295178B/zh active
- 2004-11-12 PE PE2004001111A patent/PE20050581A1/es active IP Right Grant
- 2004-11-12 NZ NZ546788A patent/NZ546788A/en unknown
- 2004-11-12 PL PL04797866T patent/PL1686964T3/pl unknown
- 2004-11-12 EP EP04797866A patent/EP1686964B9/en active Active
- 2004-11-12 BR BRPI0416227A patent/BRPI0416227B8/pt active IP Right Grant
- 2004-11-12 JP JP2006538808A patent/JP4682145B2/ja active Active
- 2004-11-12 WO PCT/EP2004/012870 patent/WO2005046645A1/en active Application Filing
- 2004-11-12 AT AT04797866T patent/ATE455537T1/de active
- 2004-11-12 AU AU2004289055A patent/AU2004289055C1/en active Active
- 2004-11-12 RU RU2006120484/15A patent/RU2404749C2/ru active
- 2004-11-12 PT PT04797866T patent/PT1686964E/pt unknown
-
2006
- 2006-04-27 IL IL175286A patent/IL175286A/en active IP Right Grant
- 2006-05-11 MA MA29019A patent/MA28155A1/fr unknown
- 2006-05-12 EC EC2006006565A patent/ECSP066565A/es unknown
- 2006-05-23 IS IS8480A patent/IS8480A/is unknown
- 2006-06-14 NO NO20062777A patent/NO337172B1/no active Protection Beyond IP Right Term
-
2007
- 2007-01-04 HK HK07100155.4A patent/HK1093682A1/xx unknown
-
2010
- 2010-03-09 CY CY20101100222T patent/CY1110293T1/el unknown
- 2010-04-01 HR HR20100190T patent/HRP20100190T1/hr unknown
- 2010-06-08 US US12/796,132 patent/US8188037B2/en active Active
-
2012
- 2012-04-26 US US13/456,681 patent/US20120214749A1/en not_active Abandoned
-
2015
- 2015-03-26 CY CY2015011C patent/CY2015011I1/el unknown
- 2015-04-29 LU LU92701C patent/LU92701I2/xx unknown
-
2016
- 2016-02-02 NO NO2016003C patent/NO2016003I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0416227B8 (pt) | micropartículas compreendendo análogos de somatostatina, seu uso, composição famacêutica e kit | |
SV2008002612A (es) | Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo | |
BRPI0512374A (pt) | agentes auxiliares de moagem de cimento | |
UY30319A1 (es) | Formulaciones de inhibidores de dpp iv | |
UY27720A1 (es) | Aroilpiridinonas monocíclicas, | |
IL232409A0 (en) | 3033*a-hla- reduced 1wt peptide and pharmaceutical compound containing it | |
IL215334A0 (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
EP1778217A4 (en) | STABLE INJECTABLE COMPOSITION OF ALPHA-TOCOPHERYLSUCCINATE; ANALOGUE AND SALTS FROM IT " | |
EP1793803A4 (en) | EASY TO IMPLANT ACTIVE COMPOSITIONS WITH DELAYED RELEASE | |
EP1708719A4 (en) | AQUEOUS PHARMACEUTICAL COMPOSITIONS OF 2,6-DIISOPROPYLPHENOL (PROPOFOL) AND THEIR USE | |
BRPI0519312A2 (pt) | composiÇço biologicamente ativa, composiÇço de liofilizaÇço, mÉtodo para a liofilizaÇço de virossomas utilizando as composiÇÕes, liofilizado de virossoma, mÉtodo para reconstituiÇço de um liofilizado de virossoma, uso de qualquer uma das composiÇÕes, kit, e, uso de um derivado de colesterila catiânico | |
BRPI0617294B8 (pt) | composição farmacêutica em gel hidroalcóolico e uso de testosterona | |
NO20062111L (no) | 2-(3,4-dimetylfenyl)-4-{[2-hydroksy-3'(1H-tetrazol-5-yl)]-hydrazon}-5-metyl-2,4-dihydropyrozol-3-on kolin. | |
DK1467724T3 (da) | Farmaceutisk sammensætning med agomelatin til dispergering i mundhulen | |
PL1973423T3 (pl) | Preparat zawierający kompozycję zawierającą polifenole i izomaltulozę | |
BRPI0514074A (pt) | aperfeiçoamentos em composições em bloco para lavatório | |
CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
CU20090200A7 (es) | Una composición de liberación prolongada que comprende un derivado de somatostatina en micropartículas | |
WO2009068708A8 (es) | Composición farmacéutica de liberación sostenida de somatostatina o un análogo suyo | |
DE60305728D1 (de) | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT VERLuNGERTER FREISETZUNG | |
DE602004024220D1 (de) | Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung | |
CL2004000535A1 (es) | Composicion farmaceutica que comprende rapamicina o un derivado de rapamicina y pimecrolimus; y su uso para el tratamiento de enfermedad inflamatoria del intestino. | |
EP1478353A4 (en) | PHARMACEUTICAL COMPOSITION WITH DELAYED RELEASE | |
CL2004001317A1 (es) | Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h | |
BRPI0411820A (pt) | composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/16 , A61K 38/31 Ipc: A61K 38/31 (2006.01), A61K 9/16 (2006.01), A61P 5/ |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/06/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B25A | Requested transfer of rights approved |
Owner name: RECORDATI AG (CH) |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |